Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.20% |
| Dec 31, 2025 | -36.21% |
| Sep 30, 2025 | -8.13% |
| Jun 30, 2025 | 7.32% |
| Mar 31, 2025 | 3.17% |
| Dec 31, 2024 | 25.77% |
| Sep 30, 2024 | -11.35% |
| Jun 30, 2024 | -16.37% |
| Mar 31, 2024 | -55.32% |
| Dec 31, 2023 | 62.98% |
| Sep 30, 2023 | -29.31% |
| Jun 30, 2023 | -6.01% |
| Mar 31, 2023 | -17.69% |
| Dec 31, 2022 | 6.61% |
| Sep 30, 2022 | -16.79% |
| Jun 30, 2022 | -20.92% |
| Mar 31, 2022 | -30.96% |
| Dec 31, 2021 | -28.09% |
| Sep 30, 2021 | -15.06% |
| Dec 31, 2020 | 6.23% |
| Sep 30, 2020 | -22.40% |
| Jun 30, 2020 | 6.13% |
| Mar 31, 2020 | -13.78% |
| Dec 31, 2019 | -27.44% |
| Sep 30, 2019 | 40.87% |
| Jun 30, 2019 | 1.67% |
| Mar 31, 2019 | 23.83% |
| Dec 31, 2018 | -25.68% |
| Sep 30, 2018 | 81.00% |
| Jun 30, 2018 | 8.89% |
| Mar 31, 2018 | 42.47% |
| Dec 31, 2017 | 93.73% |
| Sep 30, 2017 | 85.26% |
| Jun 30, 2017 | 33.35% |
| Mar 31, 2017 | -23.67% |
| Dec 31, 2016 | 55.36% |
| Sep 30, 2016 | 77.50% |